KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Long-Term Debt Issuances (2017 - 2018)

Sarepta Therapeutics has reported Long-Term Debt Issuances over the past 3 years, most recently at $18.2 million for Q4 2018.

  • For Q4 2018, Long-Term Debt Issuances fell 96.64% year-over-year to $18.2 million; the TTM value through Dec 2023 reached $18.2 million, down 70.97%, while the annual FY2022 figure was $1.1 billion, N/A changed from the prior year.
  • Long-Term Debt Issuances for Q4 2018 was $18.2 million at Sarepta Therapeutics, down from $44.4 million in the prior quarter.
  • Over five years, Long-Term Debt Issuances peaked at $540.4 million in Q4 2017 and troughed at -$133000.0 in Q3 2015.
  • A 3-year average of $110.9 million and a median of $44.4 million in 2018 define the central range for Long-Term Debt Issuances.
  • On a YoY basis, Long-Term Debt Issuances climbed as much as 96.64% in 2018 and fell as far as 96.64% in 2018.
  • Year by year, Long-Term Debt Issuances stood at $399000.0 in 2015, then surged by 135333.58% to $540.4 million in 2017, then plummeted by 96.64% to $18.2 million in 2018.
  • Business Quant data shows Long-Term Debt Issuances for SRPT at $18.2 million in Q4 2018, $44.4 million in Q3 2018, and $77.1 million in Q2 2018.